RxDoctor Payments DataLook up a doctor →

David Conyack, DO

Pain Medicine · Livingston, NJNPI 1558402768

Payments from drug & device makers

$8,241in general payments, 2019–2025

Across 528 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$2K
  • Abbott$777
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$491
  • Biodelivery Sciences International, Inc.$486
  • AbbVie$433
  • Arbor Pharmaceuticals, Inc.$417
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$8,13299%
  • Education$1101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,241 in reported general payments places this provider in the 85th percentile of 256 pain medicine providers in New Jersey.

See all pain medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$100,155
Medicare patients
256
Services billed
1,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl30$56,235
OxycontinOxycodone Hcl82$46,753
Xtampza ErOxycodone Myristate79$40,638
NucyntaTapentadol Hcl45$33,806
BelbucaBuprenorphine Hcl42$23,787
MovantikNaloxegol Oxalate50$22,105
MotegrityPrucalopride Succinate20$11,708
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen481$10,518
Fentanyl115$9,932
Buprenorphine52$8,961
LinzessLinaclotide12$8,698
Naloxone Hcl120$7,917
Oxycodone Hcl510$7,596
Tramadol Hcl ErTramadol Hcl60$4,467
Morphine Sulfate ErMorphine Sulfate96$3,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er, Nucynta, Belbuca$1,914$154,466196 claims
Redhill Biopharma Inc.Movantik$57$22,10550 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$33$11,70820 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$21$9,23570 claims
AbbVieLinzess$433$8,69812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 256 pain medicine providers in New Jersey.

Other pain medicine in Livingston

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →